SARC032-SU2C

April 7, 2021

A Phase II Randomized Controlled Trial of Neoadjuvant Pembrolizumab With Radiotherapy and Adjuvant Pembrolizumab in Patients With High-Risk, Localized Soft Tissue Sarcoma of the Extremity

TYPE OF SARCOMA: Soft Tissue Sarcoma of the Extremity
DRUG: Pembrolizumab

ACCRUAL STATUS: Now recruiting for patients

OVERALL STUDY PRINCIPAL INVESTIGATOR:
David Kirsch, MD, PhD
Professor, Radiation Oncology / Professor of Pharmacology and Cell Biology
Duke University

CLINICALTRIALS.GOV IDENTIFIER: NCT03092323

FOR STUDY DETAILS AND ELIGIBILITY CRITERIA: CLINICALTRIALS.GOV

To learn more about this study view Dr. Kirsch’s SARC032 presentation at the 2021 SARC Semiannual Meeting:

To contact the study research staff:

CONTACT SARC

Back to top